Mirum Pharmaceuticals’ Atebrioz won FDA approval for fibrodysplasia ossificans progressiva (FOP), adding a third approved option for the ultra-rare condition characterized by progressive bone growth in soft tissues. The oral pill is positioned to offer practical advantages versus existing therapies for patients and prescribers managing lifelong disease progression.